The following features of our study are significant: (1) correlation between KRAS mutation and glucose uptake is recapitulated in ICC tumors, and (2) metabolic tumor volume on 18F-FDG-PET may provide useful information as a surrogate for prognosis, reflecting the impact of KRAS mutation on survival. This evidence concerns the gene KRAS and neoplasm.